Seractide CAS:12279-41-3

Seractide is a polypeptide hormone corresponding to thirty-nine amino acids of human corticotropin that differs from full-length human corticotropin at four positions. Seractide is potent endogenous melanocortin receptor 2 (MC ) agonist. Seractide stimulates the cortex of the adrenal gland and boosts the synthesis of corticosteroids, mainly glucocorticoids but also sex steroids (androgens). Seractide, was approved by FDA in 1978, but was never marketed. The Seractide, that was ultimately withdrawn by FDA in 2014 for safety reasons.

This peptide is the acetate salt of full length (39 aminosyre) human corticotropin. It has a US approved name (USAN) but no international approved name (VERTSHUS) and does not appear on the US FDA current drug list. This appears to be a discontinued injectable repository from of corticotropin.